[{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"Second Affiliated Hospital, Zhejiang University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fordine","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase IV","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"WanBangDe Pharmaceutical \/ Second Affiliated Hospital, Zhejiang University","highestDevelopmentStatusID":"11","companyTruncated":"WanBangDe Pharmaceutical \/ Second Affiliated Hospital, Zhejiang University"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"Ganzhou City People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fordine","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase IV","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"WanBangDe Pharmaceutical \/ Ganzhou City People's Hospital","highestDevelopmentStatusID":"11","companyTruncated":"WanBangDe Pharmaceutical \/ Ganzhou City People's Hospital"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"Zhejiang Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fordine","moa":"Acetylcholinesterase","graph1":"Undisclosed","graph2":"Phase I","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"WanBangDe Pharmaceutical \/ Zhejiang Hospital","highestDevelopmentStatusID":"6","companyTruncated":"WanBangDe Pharmaceutical \/ Zhejiang Hospital"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fordine","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Controlled Release","sponsorNew":"WanBangDe Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"WanBangDe Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Ginkgo Biloba","moa":"Sodium-dependent noradrenaline transporter; Phospholipase A2, membrane associated; Glycine receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit beta-2; Gamma-aminobutyric acid receptor subunit gamma-2; Amine oxidase [flavin-containing] A; Nitric oxide synthase, inducible","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WanBangDe Pharmaceutical \/ The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine","highestDevelopmentStatusID":"11","companyTruncated":"WanBangDe Pharmaceutical \/ The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"WanBangDe Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Bromhexine Hydrochloride","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"WanBangDe Pharmaceutical \/ WanBangDe Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"WanBangDe Pharmaceutical \/ WanBangDe Pharmaceutical"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"WanBangDe Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Bromihexine HCl","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"WanBangDe Pharmaceutical \/ WanBangDe Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"WanBangDe Pharmaceutical \/ WanBangDe Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by WanBangDe Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Alzheimer Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 15, 2025

                          Lead Product(s) : Fordine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cognitive Dysfunction-associated with Brain Injuries.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 26, 2024

                          Lead Product(s) : Fordine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Ganzhou City People's Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 26, 2024

                          Lead Product(s) : Fordine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Zhejiang Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Postoperative Cognitive Complications-associated with Subarachnoid Hemorrhage.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 29, 2022

                          Lead Product(s) : Fordine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Second Affiliated Hospital, Zhejiang University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Lead Product(s) : Bromihexine HCl

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Recipient : Second Affiliated Hospital of Wenzhou Medical University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Bromihexine HCl is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 17, 2020

                          Lead Product(s) : Bromihexine HCl

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Second Affiliated Hospital of Wenzhou Medical University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Lead Product(s) : Ginkgo Biloba

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase IV

                          Sponsor : The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Ginkgo Biloba is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Angina Pectoris-associated with Depression.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 27, 2020

                          Lead Product(s) : Ginkgo Biloba

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase IV

                          Sponsor : The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Bromhexine HCl is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Pneumonia-associated with COVID-19.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 18, 2020

                          Lead Product(s) : Bromhexine Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Recipient : Second Affiliated Hospital of Wenzhou Medical University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank